

---

## ExpreS<sup>2</sup>ion licenses groundbreaking CRISPR/Cas9 gene editing technology from ERS Genomics

ExpreS<sup>2</sup>ion Biotech Holding AB (“ExpreS<sup>2</sup>ion”) announces the signing of a non-exclusive license agreement with ERS Genomics, providing ExpreS<sup>2</sup>ion with the right to use and commercialise products, for its own use or together with customers or partners, based on the highly efficient CRISPR/Cas9 gene editing technology. This will enable the Company to offer a whole new range of solutions for the next generation of vaccines, immunotherapy and diagnostics.

The CRISPR/Cas9 gene editing technology was derived from a natural defence mechanism found in bacteria, and in recent years it has created a revolution in the field of biotechnology. It is a simple and yet extremely powerful tool, which has dramatically improved our ability to edit specific genes quickly and precisely, making it possible to essentially alter the blueprints for the molecules in a cell in new ways.

For ExpreS<sup>2</sup>ion, this technology enables targeted, fast and efficient modifications of the Company’s ExpreS<sup>2</sup> protein production platform to further optimise and adjust it for specific processes or functions. This will facilitate fast development of functionally modified platforms for production of products that e.g. have improved immunity for next-generation vaccines and immunotherapy. These new products and market segments are expected to open new revenue streams for the Company, starting already this year. No financial details of the agreement are disclosed.

*“By implementing the CRISPR/Cas9 gene editing technology, ExpreS<sup>2</sup>ion has gained important competencies and strengthened our position in our field. It will also improve our ability to work seamlessly with leading academic institutions and private companies. I am certain that our new competencies and upcoming range of unique solutions based on this agreement will create excitement among many of our customers and partners. We are furthermore looking forward to using this powerful tool in our own and potentially also AdaptVac’s development projects,” says ExpreS<sup>2</sup>ion’s CEO Dr. Steen Klysner.*

### **About ERS Genomics**

ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; livestock; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit [www.ersgenomics.com](http://www.ersgenomics.com).

### **Certified Adviser**

Svensk Kapitalmarknadsgranskning AB  
Telephone: +46 70 755 95 51  
E-mail: [ca@skmg.se](mailto:ca@skmg.se)

### **For further information about ExpreS<sup>2</sup>ion Biotech Holding AB, please contact:**

Dr. Steen Klysner, CEO  
Telephone: +45 2062 9908  
E-mail: [sk@expres2ionbio.com](mailto:sk@expres2ionbio.com)

*This press release contains information that ExpreS<sup>2</sup>ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on July 1, 2019.*

**About ExpreS<sup>2</sup>ion**

ExpreS<sup>2</sup>ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS<sup>2</sup>ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS<sup>2</sup>, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS<sup>2</sup>ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017. For additional information, please visit [www.expres2ionbio.com](http://www.expres2ionbio.com) and [www.adaptvac.com](http://www.adaptvac.com).